Phigenix Can’t Appeal Immunogen’s Kadcyla Patent Win

Jan. 9, 2017, 6:31 PM

Phigenix Inc.'s loss in a challenge to Immunogen Inc.'s patent underlying breast cancer drug Kadcyla can’t be appealed, the U.S. Court of Appeals for the Federal Circuit said Jan. 9 (Phigenix, Inc. v. Immunogen, Inc., 2017 BL 4540, Fed. Cir., 2016-1544, 1/9/17).

The court held in 2014 that a third party, such as Consumer Watchdog, lacks standing to appeal a Patent Trial and Appeal Board decision favoring a patent owner because an advocacy organization can’t point to the harm it suffers.

This opinion expands the bar. Phigenix and Immunogen provide products and services to the same market, ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.